[Cardiovascular disease and systemic inflammatory diseases]

Area of Science:

• Cardiovascular Medicine
• Rheumatology
• Immunology

Background:

• Atherosclerosis is increasingly understood as an inflammatory process, not solely infiltrative or thrombogenic.
• Systemic inflammatory diseases, such as rheumatoid arthritis and systemic lupus erythematosus, are linked to accelerated atherosclerosis.
• Pathophysiological links and epidemiological evidence support the connection between inflammatory diseases and cardiovascular risk.

Purpose of the Study:

• To highlight the inflammatory nature of atherosclerosis.
• To emphasize the elevated cardiovascular risk in patients with systemic inflammatory diseases.
• To discuss the potential for modifying atherosclerotic progression through inflammatory disease treatment.

Main Methods:

• Review of existing epidemiological and imaging studies.
• Analysis of pathophysiological mechanisms linking inflammation and atherosclerosis.
• Discussion of current limitations in cardiovascular risk assessment for these patient groups.

Main Results:

• Systemic inflammation is a key driver of the atherosclerotic process.
• Treatments targeting inflammatory diseases can impact the course of atherosclerosis.
• Current cardiovascular risk scales are inadequate for patients with systemic inflammatory diseases.

Conclusions:

• Atherosclerosis is fundamentally an inflammatory disease.
• Managing systemic inflammation is crucial for cardiovascular health in affected patients.
• Development of specific cardiovascular risk assessment tools incorporating inflammatory markers is necessary.